Diagnostic and Interventional Cardiology

The father of transradial artery access, Ferdinand Kiemeneij, M.D., Ph.D., interventional cardiologist, The Netherlands ...

February 16, 2018

Videos | Mobile Devices

VIDEO: Introducing Augmented Reality

DAIC Editor Dave Fornell previews the launch of augmented reality (AR) technology in the March/April 2018 issue of DAIC ...

February 16, 2018

Illustration of the EkoSonic catheter aiding drug-dispersion in a DVT clot. Catheter directed thrombolysis of deep vein thrombosis.

Feature | Deep Vein Thrombosis (DVT) | Sanjay Pandya, M.D.

Tibial Venous Access to Treat DVT Easier on Patients

There are few downsides to using tibial venous access to treat deep vein thrombosis (DVT) with catheter-directed ...

February 16, 2018

Sponsored Content

ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services

Feature | Information Technology

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...

March 21, 2024

Technology | Thrombectomy Devices

Stryker Trevo Retriever Thrombectomy Device Approved for Stroke Treatment Up to 24 Hours

The U.S. Food and Drug Administration (FDA) has expanded the indication for Stryker's Trevo Retriever as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset, increasing the treatment window by 18 hours. The expanded indication of Stryker's clot-removal device is in line with the recently updated treatment guidelines from the American Heart Association (AHA) and American Stroke Association (ASA), and has the potential to reduce disability and improve quality of life for tens of thousands of additional stroke patients each year.

February 15, 2018

News | Hemodynamic Support Devices

Abiomed Receives Expanded Impella Approval for Cardiomyopathy With Cardiogenic Shock

Abiomed Inc. announced that it received an expanded U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps to provide treatment for heart failure associated with cardiomyopathy leading to cardiogenic shock. This approval expands the previous FDA indication for acute myocardial infarction (AMI) cardiogenic shock and post-cardiotomy cardiogenic shock (PCCS), received in April 2016.

February 15, 2018

News | Advanced Visualization

NIH Issues $2.2 Million Grant for Augmented Reality Cardiac Hologram Research

February 15, 2018 — The National Institutes of Health (NIH) awarded a $2.2 million research grant to healthcare ...

February 15, 2018

Sponsored Content

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability to diagnose cardiac disease with greater accuracy and precision

Feature | Cardiac Imaging

SPONSORED CONTENT: Finding the Right Solution

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

March 05, 2024

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.

Feature | Heart Valve Technology

Edwards Lifesciences Self Expanding TAVR Valve Gains European Approval

February 15, 2018 — Edwards Lifesciences Corp. has received European CE mark clearance for its self-expanding Centera ...

February 15, 2018

Abiomed Impella percutaneous ventricular assist device (pVAD) heart pump gains FDA PMA for high risk PCI.

Feature | Hemodynamic Support Devices

FDA Expands Impella Indication for High-risk PCI Procedures

February 14, 2018 — Abiomed Inc. announced it received an expanded U.S. Food and Drug Administration (FDA) pre-market ...

February 14, 2018

Technology | Clinical Decision Support

FDA Clears First AI-Powered Clinical Decision Support Software for Stroke

February 14, 2018 — The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact ...

February 14, 2018

Sponsored Content

Blog

BLOG: Combining Local Impedance with Contact Force to Perform RF Ablation

When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...

December 11, 2023

The Boston Scientific Essentio MRI-safe pacemaker.

Feature | Pacemakers | Dave Fornell

New Pacemaker Technologies

There have been several advancements in pacemaker technologies over the past few years. This is an overview of some of ...

February 13, 2018

News | Antiplatelet and Anticoagulation Therapies

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial

Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet therapy (DAPT) in patients at high risk of bleeding after implantation with a Xience everolimus-eluting coronary stent. The first patient was enrolled into the study by Prof. Emanuele Barbato, M.D., Ph.D., a cardiologist at OLV-Hospital Aalst in Belgium.

February 13, 2018